TRIO Pharmaceuticals Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $3.1M

  • Investors
  • 7

TRIO Pharmaceuticals General Information

Description

Developer of novel bispecific antibody drugs designed to generate immunogenic tumors. The company's drug offers dual-action tumor immunity-enhancing qualities aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells, enabling physicians to improve efficacy, reduce toxicity, and increase treatment affordability.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 930 Brittan Avenue
  • San Carlos
  • San Francisco, CA 94070
  • United States
+1 (619)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 930 Brittan Avenue
  • San Carlos
  • San Francisco, CA 94070
  • United States
+1 (619)

TRIO Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TRIO Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 07-Nov-2024 $3.1M Completed Pre-Clinical Trials
2. Seed Round 31-Mar-2023 Completed Startup
1. Grant 01-Sep-2022 $800K Completed Startup
To view TRIO Pharmaceuticals’s complete valuation and funding history, request access »

TRIO Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Pre-Series A
Seed
To view TRIO Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TRIO Pharmaceuticals Patents

TRIO Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026534883-A Target activation of endogenous cell death Pending 25-Sep-2023
AU-2024350163-A1 Targeted activation of endogenous cell death Pending 25-Sep-2023
EP-4784625-A2 Targeted activation of endogenous cell death Pending 25-Sep-2023
WO-2025072182-A2 Targeted activation of endogenous cell death Inactive 25-Sep-2023
WO-2025072182-A3 Targeted activation of endogenous cell death Inactive 25-Sep-2023 A61K31/635
To view TRIO Pharmaceuticals’s complete patent history, request access »

TRIO Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TRIO Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
Friedman BioVentures Venture Capital Minority
NuFund Venture Group Angel Group Minority
Purdue Ventures Not-For-Profit Venture Capital Minority
SeedFolio Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

TRIO Pharmaceuticals FAQs

  • When was TRIO Pharmaceuticals founded?

    TRIO Pharmaceuticals was founded in 2020.

  • Where is TRIO Pharmaceuticals headquartered?

    TRIO Pharmaceuticals is headquartered in San Francisco, CA.

  • What is the size of TRIO Pharmaceuticals?

    TRIO Pharmaceuticals has 9 total employees.

  • What industry is TRIO Pharmaceuticals in?

    TRIO Pharmaceuticals’s primary industry is Drug Discovery.

  • Is TRIO Pharmaceuticals a private or public company?

    TRIO Pharmaceuticals is a Private company.

  • What is the current valuation of TRIO Pharmaceuticals?

    The current valuation of TRIO Pharmaceuticals is .

  • What is TRIO Pharmaceuticals’s current revenue?

    The current revenue for TRIO Pharmaceuticals is .

  • How much funding has TRIO Pharmaceuticals raised over time?

    TRIO Pharmaceuticals has raised $5.7M.

  • Who are TRIO Pharmaceuticals’s investors?

    Myeloma Investment Fund, Friedman BioVentures, NuFund Venture Group, Purdue Ventures, and SeedFolio are 5 of 7 investors who have invested in TRIO Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process